Hazem M. Elmansy

Holmium Laser Enucleation of the Prostate: Long-Term Durability of Clinical Outcomes and Complication Rates During 10 Years of Followup

PURPOSE We assessed the long-term durability of subjective and objective outcomes and complication rates after holmium laser enucleation of the prostate. MATERIALS AND METHODS We conducted a retrospective analysis of 949 evaluable patients treated with holmium laser enucleation of the prostate between March 1998 and September 2010 at a single center. Study variables included International Prostate Symptom Score, quality of life, maximum urinary flow rate, post-void residual urine volume and prostate specific antigen. RESULTS Mean followup was 62 months. Mean preoperative post-void residual volume, maximal flow rate, International Prostate Symptom Score and quality of life were 311 ml, 7.9 ml per second, 19 and 3.8, respectively. Postoperatively all variables showed significant improvement starting at month 1 of followup and remained improved for the entire followup period. Patients with acute urinary retention represented 36% (343) of the cohort. Postoperative mean post-void residual volume was 45, 25.7 and 52 ml, mean maximal flow rate was 21.5, 24.3 and 23.4 ml per second, mean International Prostate Symptom Score was 7.3, 4.4 and 3.8, and mean quality of life was 1.7, 1 and 0.7 at 1 month, 1 year and 10 years, respectively. Persistent urge and stress incontinence were found in 1% and 0.5% of patients, respectively. Bladder neck contracture, urethral stricture and reoperation due to residual adenoma developed in 0.8%, 1.6% and 0.7% of patients. CONCLUSIONS Holmium laser enucleation of the prostate represents an effective treatment modality for men with symptomatic benign prostatic hyperplasia with a low rate of complications during a long followup. Patients who experience improvement from baseline to early followup maintain improvement at later followup.

Holmium Laser Enucleation Versus Photoselective Vaporization for Prostatic Adenoma Greater than 60 Ml: Preliminary Results of a Prospective, Randomized Clinical Trial

PURPOSE To our knowledge we report the first single center, prospective, randomized study comparing holmium laser enucleation and high performance GreenLight™ prostate photoselective vaporization as surgical treatment of prostatic adenomas greater than 60 ml. MATERIALS AND METHODS A total of 80 patients with a large prostatic adenoma were randomly assigned to surgical treatment with holmium laser enucleation or photoselective vaporization. International Prostate Symptom Score, International Index of Erectile Function-15, maximum flow rate, post-void residual urine, serum prostate specific antigen and transrectal ultrasound volume were recorded. RESULTS Patient baseline characteristics were similar for holmium laser enucleation and photoselective vaporization. Operative time and catheter removal time were almost equal in the 2 groups (p = 0.7 and 0.2, respectively). Eight vaporization cases were converted to transurethral prostate resection or holmium laser enucleation intraoperatively due to bleeding. A significantly higher maximum flow rate and lower post-void residual urine were noted in holmium laser cases during the entire followup (at 1 year each p = 0.02). However, no significant difference in International Prostate Symptom Score, quality of life or International Index of Erectile Function-15 was detected. Prostate volume and serum PSA decreased 78% and 88% in the holmium laser group, and 52% and 60% in the vaporization group, respectively. CONCLUSIONS Holmium laser enucleation and photoselective vaporization are effective for lower urinary tract symptoms due to a large prostatic adenoma. Early subjective functional results (maximum flow rate and post-void residual urine) of holmium laser enucleation appear to be superior to those of photoselective vaporization. In our hands cases intended to be treated with photoselective vaporization were at 22% risk of conversion to another modality. This could reflect our determination to vaporize to the capsule in all vaporization cases.

Holmium laser ablation versus photoselective vaporization of prostate less than 60 cc: long-term results of a randomized trial.

PURPOSE We evaluated the long-term results and durability of photoselective vaporization and holmium laser ablation as surgical treatment of small to medium prostates in a prospective, randomized study in men with obstructive benign prostatic hyperplasia. MATERIALS AND METHODS From March 2005 to April 2007 we randomly allocated 109 patients with a prostate gland of less than 60 cc to prostate photoselective vaporization (52) or holmium laser ablation (57) and evaluated them 1, 2 and 3 years postoperatively. Functional followup included measurement of maximum urinary flow rate, post-void residual urine, International Prostate Symptom Score, quality of life, International Index of Erectile Function and prostate specific antigen. RESULTS Mean ± SD preoperative prostate volume was 33.1 ± 14.5 and 37.3 ± 13.6 in the laser ablation and vaporization groups, respectively. All functional parameters improved significantly compared to baseline values in each group. There was no difference in International Prostate Symptom Score, quality of life, maximum urinary flow rate, post-void residual urine or percent of prostate specific antigen decrease between the 2 groups 1, 2 and 3 years postoperatively. At 3-year followup International Prostate Symptom Score had improved by 70.5%, quality of life had improved by 69.4%, maximum urinary flow rate had increased by 164% and post-void residual urine had decreased by 81% in the holmium laser ablation group. In the photoselective vaporization group International Prostate Symptom Score improved by 64.1%, quality of life improved by 65.5%, maximum urinary flow rate increased by 189% and post-void residual urine decreased by 79.5%. The overall re-treatment rate was 15.8% for holmium laser ablation vs 19.3% for photoselective vaporization. CONCLUSIONS Prostate photoselective vaporization and holmium laser ablation are effective surgical treatments for benign prostatic hyperplasia. Postoperative functional improvements were significant and durable, and equivalent in the 2 groups. The 2 techniques have a similar complication rate.

Male Sexual Function Outcome After Three Laser Prostate Surgical Techniques: A Single Center Perspective

OBJECTIVE To assess the change and predictors of sexual-related outcomes after laser prostate surgery. METHODS This is a longitudinal study of 216 sexually active men who underwent laser prostatectomy between 2005 and 2010. The International Index of Erectile Function-15 questionnaire was used both preoperatively and during the first year of follow-up. Cases with unreliable answers or patients without interested partners were excluded. All relevant data of both groups were depicted and statistically analyzed. RESULTS We identified 191 patients that met the inclusion criteria, 99 holmium laser enucleation of the prostate, 34 holmium laser ablation, and 58 photoselective vaporization of the prostate (GreenLight-532-mm laser photoselective vaporization of the prostate). There were significant differences among the 3 groups regarding the International Index of Erectile Function-15 direction of change at 1 year, being unchanged in (22.2%, 24.4%, and 29.3%), improved in (60.6%, 29.4%, and 41.4), and declined in (17.2%, 41.2%, and 29.3%) in the 3 groups, respectively (P < .05). After adjusting for clinical and perioperative variables, the independent risk factors for decline in the International Index of Erectile Function score were basal International Index of Erectile Function ≥ 55 and energy to prostate ratio. In holmium laser enucleation of the prostate group, there was significant improvement of the mean overall score, erectile function, desire, and intercourse satisfaction domains (P < .05). In holmium laser ablation and photoselective vaporization of the prostate groups, there were no significant changes between mean preopeative and postoperative scores (P > .05). The incidence of new onset retrograde ejaculation in the holmium laser enucleation of the prostate group was (77.3%) significantly different compared to (31.1%) in the holmium laser ablation group and (33.2%) in photoselective vaporization of the prostate group (P < .05). CONCLUSION Laser prostate surgery using more size-related laser energy might have possible negative influence on sexual function. Patients with normal preoperative sexuality are more at risk.

Prostatic-specific Antigen Velocity After Holmium Laser Enucleation of the Prostate: Possible Predictor for the Assessment of Treatment Effect Durability for Benign Prostatic Hyperplasia and Detection of Malignancy

OBJECTIVES To evaluate the prostate-specific antigen velocity (PSAV) as an indicator for effectiveness and durability of size reduction after holmium laser enucleation of the prostate (HoLEP). Additionally, PSAV monitoring in the detection of prostate cancer was also evaluated. METHODS Between 1998 and 2006, we reviewed the prostate-specific antigen (PSA) data of 335 men who underwent HoLEP and had a complete PSA data including preoperative PSA, postoperative PSA (reset), and a minimum of 2 annual PSA readings after PSA reset. PSAV was calculated by 3 methods--simple arithmetic method, linear regression method, and rate method. RESULTS In the benign group, the mean PSA dropped from 5.44 to 0.91 ng/mL (P <0.001). The prostate cancer patients who were newly discovered in the follow-up period had significantly higher baseline PSA (P = .032) and significantly lower PSA reduction than that of the benign group (75.39% vs 47.49%, P <.001). PSAV was calculated by 3 different methods and produced identical results; however, linear regression method produced significantly lower estimates at 7 years. In the malignant group, the mean PSAV at 1 and 3 years was higher than that of the benign group (1.28 vs 0.13 and 2.4 vs 0.09, P <0.022, 0.001, respectively). CONCLUSIONS HoLEP results in a significant reduction in PSA that remained at lower levels during follow-up, suggesting that the glandular size reduction after HoLEP is durable. Monitoring of PSAV is important in long-term follow-up of patients for prostatic carcinoma detection after prostatic surgery.

Feasibility of holmium laser enucleation of the prostate (HoLEP) for recurrent/residual benign prostatic hyperplasia (BPH)

Study Type – Therapy (case series)

Holmium laser enucleation of the prostate: modified technical aspects.

There is an increasing interest in holmium laser enucleation of the prostate (HoLEP) as the new standard for the surgical management of BPH of any size, replacing open prostatectomy and TURP [1]. The results of HoLEP, as evidenced by PSA data, TRUS, the weight of tissue resected, urodynamic variables and data from many randomized trials, systematic reviews and meta-analyses, confirmed the effectiveness and durability of this technique [2–7]. HoLEP reproduces the removal of the whole obstructing adenoma (transitional zone) of the prostate by surgical enucleation, similar to the technique of using the index finger in open prostatectomy. HoLEP is equally suitable for small, medium and large prostate glands, with clinical outcomes that are independent of prostate size, and recently it has been proposed as a new standard for treating symptomatic BPH [8,9] HoLEP is also a safe and effective therapy in patients on anticoagulation and with symptomatic BPH refractory to medical therapy [10].

Holmium:YAG Transurethral Incision Versus Laser Photoselective Vaporization for Benign Prostatic Hyperplasia in a Small Prostate

PURPOSE We assess the perioperative, short-term and long-term functional outcomes of treating bladder outlet obstruction secondary to a small prostate by 1 of 2 laser techniques. MATERIALS AND METHODS A retrospective review using a prospectively maintained database was performed of patients treated for bladder outlet obstruction secondary to a prostate smaller than 40 ml. Patients who were treated with GreenLight™ photoselective vaporization of the prostate or holmium laser transurethral incision of the prostate were included in the study. RESULTS From January 2002 through December 2010, 191 cases of 1,682 laser prostate surgeries were described. GreenLight photoselective vaporization of the prostate was performed in 144 (75.4%) cases and holmium laser transurethral incision of the prostate was performed in 47 (24.6%) cases. A significantly shorter mean operating time, hospital stay and catheter duration were observed in the holmium laser transurethral incision of the prostate group (30.3 ± 16 minutes, 0.8 ± 0.8 days and 1.3 ± 1.9 days, respectively) than in the photoselective vaporization of the prostate group (45.8 ± 22 minutes, 0.3 ± 0.4 days and 0.4 ± 0.6 days, respectively, p <0.05). At 1 and 5 years after photoselective vaporization of the prostate there were reductions in mean International Prostate Symptom Score, quality of life score and residual urine with improvement in mean maximal flow rate of 57.7% and 62.8%, 58.3% and 57.2%, 65.4% and 73%, and 127.6% and 167.1%, respectively. At 1 and 5 years after holmium laser transurethral incision of the prostate there were reductions in mean International Prostate Symptom Score, quality of life score and residual urine with improvement of mean maximal flow rate of 55.3% and 52.8%, 49.2% and 49%, 45% and 78.1%, and 67.4% and 35.4%, respectively. Subjective and objective urine flow parameters were comparable at different followup points. There was no significant difference between the 2 groups in terms of early and late complications (p >0.05). Reoperation rates were 10.4% and 6.4% in the photoselective vaporization of the prostate and holmium laser transurethral incision of the prostate groups, respectively (p >0.05). The mean estimated cost per holmium laser transurethral incision of the prostate procedure was significantly lower than per photoselective vaporization of the prostate procedure (509.34CAD vs 1,765.92CAD, p = 0.002). CONCLUSIONS Holmium laser transurethral incision of the prostate and GreenLight photoselective vaporization of the prostate seem to be equally effective, safe and durable surgical treatment options for small prostates even in high risk patients.

Two Laser Ablation Techniques for a Prostate Less Than 60 mL: Lessons Learned 70 Months After a Randomized Controlled Trial

OBJECTIVE To report lessons learned and predictors of long-term outcome after a randomized trial comparing 2 widely available lasers (2123 nm and 532 nm) in prostate ablation as treatment of symptomatic benign prostatic hyperplasia. METHODS Between March 2005 and April 2007, 109 patients with a prostate volume of less than 60 mL were recruited and randomized to treatment: 57 underwent holmium laser ablation of the prostate (HOLAP) and 52 underwent photoselective vaporization of the prostate (PVP) using an 80-W potassium titanyl phosphate laser. The changes in subjective (International Prostate Symptom Score quality of life and International Index of Erectile Function-15) and objective (postvoid residual urine maximal flow rate) outcome parameters were compared. The long-term outcome, timing, and predictors of negative outcome were assessed. Cost analysis was included. RESULTS After a median of 71.3 months, significant comparable improvement was documented in all subjective and objective urinary parameters from baseline measures at different points of follow-up. Retreatment for infravesical obstruction was 19.2% in HOLAP and 25% in PVP (P >.05). Smaller prostate volume was significantly associated with bladder neck contracture (BNC) after laser ablation, regardless the type of laser used. BNC and de novo urethral stricture seem to be the main causes for an early (first-year) reintervention. Redo treatment for recurring prostate adenoma was associated with less postoperative prostate-specific antigen reduction (<20%). Procedure costs were CaD

Is there a way to predict stress urinary incontinence after holmium laser enucleation of the prostate

200.45 higher in the PVP group (P >.05). CONCLUSION PVP and HOLAP seem to be equally effective and safe, with similar long-term outcome data, including cost. Regardless the laser wavelength, at least 1 of 5 patients will need retreatment. BNC is a more prevalent cause of early retreatment in smaller glands with both lasers. Postoperative prostate-specific antigen reduction of less than 20% warrants careful follow-up for recurrent symptoms secondary to residual prostate tissue.